Sector News

Centessa’s new chief medical officer has AstraZeneca’s Tagrisso, Lynparza on his resume

May 16, 2021
Life sciences

The resume of Antoine Yver, M.D., includes several of AstraZeneca’s most well-known approved cancer drugs and who’s who of Big Pharma. He will now bring that expertise to Centessa Pharmaceuticals as its new chief medical officer.

Yver leaves behind a legacy of moving 11 different medicines through development to approval for AstraZeneca, which also include the Merck-partnered cancer drug Lynparza and Enhertu, the $6.9 billion partnered oncology med with Daiichi Sankyo, as well as working on its major lung cancer drug Tagrisso.

Centessa’s new executive most recently served at Daiichi Sankyo, where he was executive vice president and global head, R&D oncology, as well as chair of the Cancer Enterprise. Before that, he was AstraZeneca’s senior vice president, global medicine head, oncology, and global medicines development China lead. Yver also spent time at Merck, Johnson & Johnson and Aventis Pharmaceuticals, which is now a part of Sanofi.

“Antoine is a true industry leader with significant experience and success as a drug developer, having developed some of the most impactful oncology drugs in the world,” said Centessa CEO Saurabh Saha, M.D., Ph.D. “I look forward to partnering with him as we advance our portfolio of preclinical programs into the clinic and progress our four assets currently in clinical development.”

Yver will oversee a broader portfolio at Centessa, which focuses on overhauling the drug development process using an asset-centric R&D model. The Cambridge, Massachusetts-based company has over a dozen therapies in development, including the phase 3 clinical asset Lixivaptan in autosomal dominant polycystic kidney disease.

A number of products in Centessa’s portfolio are epidermal growth factor receptor inhibitors, which target a particular mutation common in non-small cell lung cancer and other malignancies.

“Centessa’s asset-centric model exemplifies the very best practices that I have experienced and implemented in the industry,” Yver said in a statement.

The company launched in February with a series A funding but quickly made the move to IPO. Centessa, which formed from the merger of 10 different biotechs, filed to raise $100 million and join the public markets in late April.

Yver’s appointment is the latest staff shuffle for the brand new biopharmaceutical company, which launched with Moncef Slaoui, M.D., as chief scientific officer. The Operation Warp Speed alum stepped down in March amid allegations of sexual assault at his former employer, GlaxoSmithKline.

by Annalee Armstrong

Source: fiercebiotech.com

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend